Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Northrop Grumman Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B), while Northrop Grumman Corporation trades at $484.49 (market cap $67.26B). The key difference: Northrop Grumman Corporation is far larger — about 11.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Northrop Grumman Corporation pays a 2.09% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Northrop Grumman Corporation for 81 Days on average.
| IOVA | NOC | |
|---|---|---|
Market Cap | $5.85B | $67.26B |
Volume | 14,517,176 | 711,592 |
Sector | Health | Industrials |
52-Week High | $14.82 | $768.02 |
52-Week Low | $1.81 | $473.46 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.78B | $81.24B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Northrop Grumman (NOC) trades at $484.48, up 0.28% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 12.6%. Recent news highlights the loss of a $20B Navy fighter contract to Boeing, creating near-term headwinds. Technical indicators show oversold conditions with RSI at 16.17, while the stock trades below key resistance at $484.
NOC presents a compelling value opportunity with a 15.05 P/E ratio and 26.96% ROE, supported by a 54% analyst buy rating and $615.75 price target. Risks include competitive contract losses and defense budget uncertainties, but the company's $104.7B backlog and dividend growth provide stability. The current technical weakness may offer entry points for long-term investors seeking defense exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
